


```
=> e piperidine/cn
E1      1      PIPERIDINAMINE, N-((3,4-DIMETHOXYPHENYL)METHYL)-/CN
E2      1      PIPERIDINAMINE, POLYMER WITH (CHLOROMETHYL)OXIRANE AND 4,4'-
              (1-METHYLETHYLIDENE)BIS(PHENOL) /CN
E3      1 --> PIPERIDINE/CN
E4      1      PIPERIDINE 1,2-CYCLOBUTANE DICARBOXYLATE/CN
E5      1      PIPERIDINE 1,2-CYCLOHEXANEDICARBOXYLATE/CN
E6      1      PIPERIDINE 1,2-CYCLOPENTANE DICARBOXYLATE/CN
E7      1      PIPERIDINE 1,2-CYCLOPROPANE DICARBOXYLATE/CN
E8      1      PIPERIDINE 183A/CN
E9      1      PIPERIDINE 2,4,6-TRINITROPHENOLATE/CN
E10     1      PIPERIDINE 2,4-DINITROPHENOLATE/CN
E11     1      PIPERIDINE 207E/CN
E12     1      PIPERIDINE 211B/CN
```

=> s e3

L1 1 PIPERIDINE/CN

=> d str rsd

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

Ring System Data

Elemental Analysis	Elemental Sequence	Size of the Rings	Ring Formula	Identifier	Occurrence
EA	ES	SZ	RF	RID	Count
C5N	NC5	6	C5N	46.156.1	1

=>


```
e indole/cn
E1      1      INDOLAPRILAT/CN
E2      1      INDOLBI/CN
E3      1 --> INDOLE/CN
E4      1      INDOLE 2,3-DIOXYGENASE/CN
E5      1      INDOLE 3-ACETONITRILASE/CN
E6      1      INDOLE 3-ACETYLASPARTATE HYDROLYASE/CN
E7      1      INDOLE 3-HYDROXYLASE/CN
E8      1      INDOLE ACETAMIDE HYDROLASE (AGROBACTERIUM TUMEFACIENS STRAIN
              C58 GENE TMS2)/CN
E9      1      INDOLE ACETAMIDE HYDROLASE (AZOARCUS STRAIN BH72 GENE TMS)/C
              N
E10     1      INDOLE ACETAMIDE HYDROLASE (BRADYRHIZOBIUM JAPONICUM STRAIN
              USDA110 GENE TMS2)/CN
E11     1      INDOLE ACETAMIDE HYDROLASE (BURKHOLDERIA PSEUDOMALLEI STRAIN
              K96243)/CN
E12     1      INDOLE ACETAMIDE HYDROLASE (BURKHOLDERIA XENOVORANS STRAIN L
```

B400) /CN

=> s e3
L2 1 INDOLE/CN

=> d str rsd

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

Ring System Data

Elemental Analysis	Elemental Sequence	Size of the Rings	Ring System	Ring Formula	Identifier	Occurrence
EA	ES	SZ	RF	RID	Count	
C4N-C6	NC4-C6	5-6	C8N	333.151.57	1	

FILE 'REGISTRY' ENTERED AT 07:16:00 ON 28 MAY 2009
 E PIPERIDINE/CN
 L1 1 S E3
 E INDOLE/CN
 L2 1 S E3
 L3 210333 S 46.156/RID (P) 333.151/RID
 L4 STRUC
 L5 18 SEARCH L4 SSS SUB=L3 SAMPLE

=> d 14
 L4 HAS NO ANSWERS
 L4 STR



VAR G1=8/7/12/11
 VPA 16-1/2/3 U
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 7 3
 NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

=> search 14
 ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss
 ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:13
 'L3' IS NOT A VALID SEARCH SCOPE
 ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:end
 SEARCH ENDED BY USER

=> search 14
 ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss
 ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:subset
 ENTER SUBSET L# OR (END):13
 ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):ful
 FULL SUBSET SEARCH INITIATED 07:24:35 FILE 'REGISTRY'
 FULL SUBSET SCREEN SEARCH COMPLETED - 207321 TO ITERATE

100.0% PROCESSED 207321 ITERATIONS 3811 ANSWERS
 SEARCH TIME: 00.00.05

L6 3811 SEA SUB=L3 SSS FUL L4

=> fil caplus
 COST IN U.S. DOLLARS SINCE FILE TOTAL
 FULL ESTIMATED COST ENTRY SESSION
 217.04 217.26

FILE 'CAPLUS' ENTERED AT 07:24:46 ON 28 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 May 2009 VOL 150 ISS 22
FILE LAST UPDATED: 27 May 2009 (20090527/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

CPlus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate

=> s 16
L7 169 L6

=> s 17 and 5ht?
9349 5HT?
L8 8 L7 AND 5HT?


=> d bib hitstr 8

L8 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1998:682229 CAPLUS
DN 129:302552
OREF 129:61715a,61718a
TI Preparation of 1,4-disubstituted cyclic amine derivatives as serotonin antagonists
IN Kitazawa, Noritaka; Ueno, Kohshi; Takahashi, Keiko; Kimura, Teiji; Sasaki, Atsushi; Kawano, Koki; Okabe, Tadashi; Komatsu, Makoto; Matsunaga, Manabu; Kubota, Atsuhiko
PA Eisai Co., Ltd., Japan
SO PCT Int. Appl., 635 pp.
CODEN: PIXXD2


DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9843956	A1	19981008	WO 1998-JP1481	19980331
	W: AU, CA, CN, HU, JP, KR, MX, NO, NZ, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	TW 242011	B	20051021	TW 1998-87104733	19980330
	CA 2280753	A1	19981008	CA 1998-2280753	19980331

CA 2280753	C	20071204		
AU 9865209	A	19981022	AU 1998-65209	19980331
AU 748038	B2	20020530		
ZA 9802707	A	19991020	ZA 1998-2707	19980331
EP 976732	A1	20000202	EP 1998-911137	19980331
EP 976732	B1	20041124		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
HU 2000000434	A2	20000628	HU 2000-434	19980331
HU 2000000434	A3	20020528		
NZ 337651	A	20020426	NZ 1998-337651	19980331
RU 2203275	C2	20030427	RU 1999-123039	19980331
AT 283259	T	20041215	AT 1998-911137	19980331
ES 2230681	T3	20050501	ES 1998-911137	19980331
CN 1204121	C	20050601	CN 1998-803861	19980331
JP 3953115	B1	20070808	JP 1998-541460	19980331
US 6448243	B1	20020910	US 1999-367227	19990811
NO 9904720	A	19991130	NO 1999-4720	19990928
NO 314543	B1	20030407		
HK 1026700	A1	20050826	HK 2000-105871	20000919
US 20020086999	A1	20020704	US 2001-846259	20010502
US 7071201	B2	20060704		
US 20020019531	A1	20020214	US 2001-859517	20010518
US 6579881	B2	20030617		
PRAI JP 1997-98433	A	19970331		
JP 1997-366764	A	19971226		
WO 1998-JP1481	W	19980331		
US 1999-367227	A3	19990811		
OS MARPAT 129:302552				
IT 214611-86-6P	214611-87-7P	214611-88-8P		
214611-89-9P	214616-51-0P	214616-52-1P		
214616-53-2P	214616-54-3P			
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of 1,4-disubstituted cyclic amine derivs. as serotonin antagonists)				
RN 214611-86-6	CAPLUS			
CN 1H-Indole, 1-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro-6-(4-piperidinylmethyl)-	(CA INDEX NAME)			




RN 214611-87-7	CAPLUS			
CN Ethanone, 1-[4-[(1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl)-2,3-dihydro-1H-indol-6-yl]methyl]-1-piperidinyl-	(CA INDEX NAME)			




RN 214611-88-8	CAPLUS			
----------------	--------	--	--	--

CN 1H-Indole, 6-[(1-ethyl-4-piperidinyl)methyl]-1-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro- (CA INDEX NAME)




RN 214611-89-9 CAPLUS

CN 1H-Indole, 1-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro-6-[(1-methyl-4-piperidinyl)methyl]- (CA INDEX NAME)



RN 214616-51-0 CAPLUS


CN 1H-Indole, 1-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro-6-(4-piperidinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 214616-52-1 CAPLUS

CN Ethanone, 1-[4-[(1-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro-1H-indol-6-yl)methyl]-1-piperidinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 214616-53-2 CAPLUS

CN 1H-Indole, 6-[(1-ethyl-4-piperidinyl)methyl]-1-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro-, monohydrochloride (9CI)


(CA INDEX NAME)



● HCl

RN 214616-54-3 CAPLUS

CN 1H-Indole, 1-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro-6-[(1-methyl-4-piperidinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib hitstr 7

L8 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:832788 CAPLUS
DN 137:337885
TI Preparation of heterocyclxyloxy-, heterocyclthioxy- and heterocyclaminobenzazoles as 5-hydroxytryptamine-6 (5-HT6) ligands
IN Zhou, Ping; Harrison, Boyd Lynn; Li, Yanfang
PA Wyeth, John, and Brother Ltd., USA
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002085892	A1	20021031	WO 2002-US12415	20020419
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,				

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2444095 A1 20021031 CA 2002-2444095 20020419
 AU 2002307424 A1 20021105 AU 2002-307424 20020419
 US 20030069278 A1 20030410 US 2002-126598 20020419
 US 6815456 B2 20041109
 EP 1385842 A1 20040204 EP 2002-764248 20020419
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 HU 2003003958 A2 20040428 HU 2003-3958 20020419
 CN 1518547 A 20040804 CN 2002-812308 20020419
 CN 1293072 C 20070103
 BR 2002009056 A 20040810 BR 2002-9056 20020419
 JP 2004526787 T 20040902 JP 2002-583419 20020419
 IN 2003KN01264 A 20060310 IN 2003-KN1264 20031006
 MX 2003009476 A 20040212 MX 2003-9476 20031016
 NO 2003004648 A 20031120 NO 2003-4648 20031017
 ZA 2003009004 A 20050221 ZA 2003-9004 20031119
 US 20050065186 A1 20050324 US 2004-949062 20040924
 AU 2008203389 A1 20080821 AU 2008-203389 20080729
 PRAI US 2001-285643P P 20010420
 AU 2002-307424 A3 20020419
 US 2002-126598 A3 20020419
 WO 2002-US12415 W 20020419
 OS MARPAT 137:337885
 IT 474002-60-3P 474002-62-5P 474003-38-8P
 474003-40-2P 474003-42-4P 474003-44-6P
 474003-46-8P 474003-48-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of heterocyclxyloxy-, heterocyclthioxy- and
 heterocyclaminobenzazoles as 5-hydroxytryptamine-6 (5-HT6) ligands)
 RN 474002-60-3 CAPLUS
 CN Benzenamine, 4-[(4-(4-piperidinyloxy)-1H-indol-1-yl)sulfonyl]-,
 hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 474002-62-5 CAPLUS
 CN Benzenamine, 4-[(4-(3-piperidinyloxy)-1H-indol-1-yl)sulfonyl]-,
 hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 474003-38-8 CAPLUS

CN 1H-Indole, 1-(phenylsulfonyl)-4-(3-piperidinyloxy)- (CA INDEX NAME)




RN 474003-40-2 CAPLUS

CN Benzenamine, 4-[(4-(3-piperidinyloxy)-1H-indol-1-yl)sulfonyl]- (CA INDEX NAME)




RN 474003-42-4 CAPLUS

CN 1H-Indole, 1-(1-naphthalenylsulfonyl)-4-(3-piperidinyloxy)- (CA INDEX NAME)




RN 474003-44-6 CAPLUS

CN 1H-Indole, 1-(phenylsulfonyl)-4-(4-piperidinyloxy)- (CA INDEX NAME)




RN 474003-46-8 CAPLUS

CN Benzenamine, 4-[(4-piperidinyloxy)-1H-indol-1-yl]sulfonyl- (CA INDEX NAME)



RN 474003-48-0 CAPLUS

CN 1H-Indole, 1-(1-naphthalenylsulfonyl)-4-(4-piperidinyloxy)- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib hitstr 6

L8 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2003:656767 CAPLUS
DN 139:197493
TI Preparation of heterocyclic compounds possessing affinity at 5-HT1-type receptors and uses thereof in therapy
IN Harrington, Frank Peter; Smith, Paul William; Ward, Simon E.
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2

DT Patent
LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003068772	A1	20030821	WO 2003-EP1711	20030217
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003212254	A1	20030904	AU 2003-212254	20030217
	EP 1476444	A1	20041117	EP 2003-708113	20030217
	EP 1476444	B1	20060412		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005527500	T	20050915	JP 2003-567899	20030217
	AT 323085	T	20060415	AT 2003-708113	20030217
	ES 2259759	T3	20061016	ES 2003-708113	20030217
	US 20050085458	A1	20050421	US 2004-504109	20040810
	US 7244726	B2	20070717		
PRAI	GB 2002-3804	A	20020218		
	WO 2003-EP1711	W	20030217		
OS	MARPAT 139:197493				
IT	583031-40-7P				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic				

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of piperidinyl/piperazinylalkyl substituted benzoxazines as ligands for 5-HT1A, 5-HT1B and 5-HT1D receptors and uses thereof)

RN 583031-40-7 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-6-[[1-[2-[(2-methyl-5-quinolinyl)oxy]ethyl]-4-piperidinylidene]methyl]- (CA INDEX NAME)




IT 583031-41-8P, 6-[(2-methylquinolin-5-yl)oxy]ethylpiperidin-4-ylmethyl]-1,3-dihydroindol-2-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of piperidinyl/piperazinylalkyl substituted benzoxazines as ligands for 5-HT1A, 5-HT1B and 5-HT1D receptors and uses thereof)

RN 583031-41-8 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-6-[[1-[2-[(2-methyl-5-quinolinyl)oxy]ethyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



IT 583031-25-8P, 6-(Piperidin-4-ylidenemethyl)-1,3-dihydroindol-2-one
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of piperidinyl/piperazinylalkyl substituted benzoxazines as ligands for 5-HT1A, 5-HT1B and 5-HT1D receptors and uses thereof)
 RN 583031-25-8 CAPLUS
 CN 2H-Indol-2-one, 1,3-dihydro-6-(4-piperidinylidenemethyl)- (CA INDEX NAME)




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib hitstr 5

L8 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2004:490721 CAPLUS
 DN 141:54192
 TI Preparation of aminoalkoxyindoles as 5-HT6-receptor ligands, in particular selective 5-HT6 antagonists, for treating CNS disorders
 IN Zhao, Shu-Hai
 PA F. Hoffmann-La Roche A.-G., Switz.
 SO PCT Int. Appl., 79 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
PI WO 2004050085	A1	20040617	WO 2003-EP13372	20031127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,				

GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
 LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
 OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
 TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2508315 A1 20040617 CA 2003-2508315 20031127
 AU 2003289903 A1 20040623 AU 2003-289903 20031127
 AU 2003289903 B2 20080626
 EP 1569638 A1 20050907 EP 2003-782240 20031127
 EP 1569638 B1 20070905
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 BR 2003016962 A 20051025 BR 2003-16962 20031127
 CN 1713908 A 20051228 CN 2003-80104019 20031127
 JP 2006509777 T 20060323 JP 2004-556206 20031127
 NZ 539950 A 20070531 NZ 2003-539950 20031127
 TW 284124 B 20070721 TW 2003-92133339 20031127
 AT 372113 T 20070915 AT 2003-782240 20031127
 ES 2291722 T3 20080301 ES 2003-782240 20031127
 RU 2350602 C2 20090327 RU 2005-121125 20031127
 US 20040132799 A1 20040708 US 2003-724683 20031201
 US 7084169 B2 20060801
 ZA 2005004412 A 20060426 ZA 2005-4412 20050530
 MX 2005005790 A 20051018 MX 2005-5790 20050531
 IN 2005CN01106 A 20070720 IN 2005-CN1106 20050602
 KR 755580 B1 20070906 KR 2005-710127 20050603
 PRAI US 2002-430506P P 20021203
 WO 2003-EP13372 W 20031127
 OS MARPAT 141:54192
 IT 706783-81-5P, 3-Benzene­sulfonyl-7-(piperidin-4-yloxy)-1H-indole
 monohydrochloride 706784-50-1P,
 3-Benzene­sulfonyl-7-(piperidin-4-yloxy)-1H-indole
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (5-HT6 antagonist; preparation of aminoalkoxyindoles as 5-HT6-receptor
 ligands, in particular selective 5-HT6 antagonists, for treating CNS
 disorders)
 RN 706783-81-5 CAPLUS
 CN 1H-Indole, 3-(phenylsulfonyl)-7-(4-piperidinyloxy)-, hydrochloride (1:1)
 (CA INDEX NAME)




● HCl

RN 706784-50-1 CAPLUS
CN 1H-Indole, 3-(phenylsulfonyl)-7-(4-piperidinyloxy)- (CA INDEX NAME)




IT 706784-12-5P, 4-[(3-(Benzenesulfanyl)-1H-indol-7-yl)oxy]piperidine-1-carboxylic acid tert-butyl ester 706784-15-8P,
4-[(3-(Benzenesulfanyl)-1H-indol-7-yl)oxy]piperidine-1-carboxylic acid tert-butyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of aminoalkoxyindoles as 5-HT6-receptor ligands,
in particular selective 5-HT6 antagonists, for treating CNS disorders)
RN 706784-12-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(3-(phenylthio)-1H-indol-7-yl)oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 706784-15-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(3-(phenylsulfonyl)-1H-indol-7-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib hitstr 4

L8 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2005:979638 CAPLUS

DN 143:286283

TI Preparation of 7-(4-piperidinylmethyl)indoles as potent 5-HT2a antagonists

IN Heinrich, Timo; Boettcher, Henning; Leibrock, Joachim

PA Merck Patent G.m.b.H., Germany

SO PCT Int. Appl., 38 pp.

CODEN: PIXXD2


DT Patent

LA German

FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
PI WO 2005082886	A1	20050909	WO 2005-EP1446	20050214

W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
DE 102004010132	A1 20050915	DE 2004-102004010132	20040227
AU 2005217043	A1 20050909	AU 2005-217043	20050214
CA 2557489	A1 20050909	CA 2005-2557489	20050214
EP 1718634	A1 20061108	EP 2005-715322	20050214
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS		
JP 2007523930	T 20070823	JP 2007-500098	20050214
US 20070197596	A1 20070823	US 2006-590912	20060828
PRAI	DE 2004-102004010132	A 20040227	
	WO 2005-EP1446	W 20050214	
OS	MARPAT 143:286283		
IT	1066560-13-1 1066560-14-2 1066560-15-3 1066560-16-4 1066560-17-5 1066560-18-6 1066560-19-7 1066560-20-0 1066560-21-1 1066560-22-2 1066560-23-3 1066560-24-4 1066560-25-5 1066560-26-6 1066560-27-7 1066560-28-8 1066560-29-9 1066560-30-2 1066560-31-3 1066560-32-4 1066560-33-5 1066560-34-6		
RL:	PRPH (Prophetic) (Preparation of 7-(4-piperidinylmethyl)indoles as potent 5-HT2a antagonists)		
RN	1066560-13-1 CAPLUS		
CN	Cyanic acid, 7-[(dimethylamino)[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]methyl]-2,3-dihydro-1H-indol-3-yl ester	(CA INDEX NAME)	




RN 1066560-14-2 CAPLUS

CN Cyanic acid, 7-[(1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl)hydroxymethyl]-2,3-dihydro-1H-indol-3-yl ester (CA INDEX NAME)




RN 1066560-15-3 CAPLUS

CN Benzonitrile, 4-[2-[4-[amino(3-fluoro-2,3-dihydro-1H-indol-7-yl)methyl]-1-piperidinyl]ethyl]- (CA INDEX NAME)




RN 1066560-16-4 CAPLUS

CN Cyanic acid, 7-[(1-[2-(4-cyanophenyl)ethyl]-4-piperidinyl)hydroxymethyl]-2,3-dihydro-1H-indol-3-yl ester (CA INDEX NAME)



RN 1066560-17-5 CAPLUS


CN Cyanic acid, 7-[(1-[2-(4-cyanophenyl)ethyl]-4-piperidinyl)(dimethylamino)methyl]-2,3-dihydro-1H-indol-3-yl ester (CA INDEX NAME)




RN 1066560-18-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1066560-19-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1066560-20-0 CAPLUS
CN Benzonitrile, 4-[2-[4-[[2,3-dihydro-3-(2,2,2-trifluoroacetyl)-1H-indol-7-yl](dimethylamino)methyl]-1-piperidinyl]ethyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1066560-21-1 CAPLUS
CN 1H-Indole-7-methanol, 3-fluoro- α -[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]- (CA INDEX NAME)




RN 1066560-22-2 CAPLUS

CN 1H-Indole-7-methanamine, 3-fluoro- α -[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]- (CA INDEX NAME)




RN 1066560-23-3 CAPLUS

CN Cyanic acid, 7-[(1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl)hydroxymethyl]-1H-indol-3-yl ester (CA INDEX NAME)




RN 1066560-24-4 CAPLUS

CN Cyanic acid, 7-[(dimethylamino)[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]methyl]-1H-indol-3-yl ester (CA INDEX NAME)




RN 1066560-25-5 CAPLUS


CN Benzonitrile, 4-[2-[4-[(3-fluoro-1H-indol-7-yl)hydroxymethyl]-1-piperidinyl]ethyl]- (CA INDEX NAME)



RN 1066560-26-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1066560-27-7 CAPLUS
CN Cyanic acid, 7-[(1-[2-(4-cyanophenyl)ethyl]-4-piperidinyl)hydroxymethyl]-1H-indol-3-yl ester (CA INDEX NAME)



RN 1066560-28-8 CAPLUS


CN Cyanic acid, 7-[(1-[2-(4-cyanophenyl)ethyl]-4-piperidinyl)(dimethylamino)methyl]-1H-indol-3-yl ester (CA INDEX NAME)




RN 1066560-29-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1066560-30-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



PAGE 1-A




PAGE 2-A



RN 1066560-31-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1066560-32-4 CAPLUS
CN 1H-Indole-7-methanol, 3-fluoro- α -[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro- (CA INDEX NAME)




RN 1066560-33-5 CAPLUS

CN 1H-Indole-7-methanamine, 3-fluoro-α-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro- (CA INDEX NAME)



RN 1066560-34-6 CAPLUS

CN Benzonitrile, 4-[2-[4-[(3-fluoro-2,3-dihydro-1H-indol-7-yl)hydroxymethyl]-1-piperidinyl]ethyl]- (CA INDEX NAME)




IT 864297-53-0P 864297-54-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 7-(4-piperidinylmethyl)indoles as potent 5-HT2a antagonists)


RN 864297-53-0 CAPLUS

CN 1H-Indole-7-methanol, α -[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-
(CA INDEX NAME)



RN 864297-54-1 CAPLUS

CN Methanone, [1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-1H-indol-7-yl- (CA INDEX NAME)




IT 864297-55-2P 864297-56-3P 864297-57-4P
864297-58-5P 864297-59-6P 864297-60-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 7-(4-piperidinylmethyl)indoles as potent 5-HT2a antagonists)

RN 864297-55-2 CAPLUS


CN 1H-Indole-3-carbonitrile, 7-[[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]carbonyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 864297-56-3 CAPLUS

CN 1H-Indole-7-methanol, α -[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-


2,3-dihydro- (CA INDEX NAME)




RN 864297-57-4 CAPLUS

CN Ethanone, 2,2,2-trifluoro-1-[7-[[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]hydroxymethyl]-1H-indol-3-yl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 864297-58-5 CAPLUS

CN Ethanone, 1-[7-[(dimethylamino)[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]methyl]-1H-indol-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 864297-59-6 CAPLUS

CN 1H-Indole-3-carbonitrile, 7-[(1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl)hydroxymethyl]- (CA INDEX NAME)



RN 864297-60-9 CAPLUS

CN 1H-Indole-3-carbonitrile, 7-[(1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl)carbonyl]- (CA INDEX NAME)




IT 864297-61-0 864297-62-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 7-(4-piperidinylmethyl)indoles as potent 5-HT2a antagonists)


RN 864297-61-0 CAPLUS

CN 1H-Indole-7-methanol, α -4-piperidinyl- (CA INDEX NAME)



RN 864297-62-1 CAPLUS


CN 1H-Indole-7-methanol, 2,3-dihydro- α -4-piperidinyl- (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d bib hitstr 3

L8 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:198079 CAPLUS
DN 144:362583
TI 1-(1-Phenethylpiperidin-4-yl)-1-phenylethanols as potent and highly
selective 5-HT2A antagonists
AU Heinrich, Timo; Boettcher, Henning; Pruecher, Helmut; Gottschlich, Rudolf;
Ackermann, Karl-August; van Amsterdam, Christoph
CS Preclinical Pharmaceutical Research, Merck KGaA, Darmstadt, 64293, Germany
SO ChemMedChem (2006), 1(2), 245-255
CODEN: CHEMGX; ISSN: 1860-7179
PB Wiley-VCH Verlag GmbH & Co. KGaA
DT Journal
LA English
IT 864297-53-0 864297-54-1 864297-56-3
864297-57-4 864297-59-6 864297-60-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and structure activity relations of
(phenethylpiperidinyl)phenylethanols as potent and highly selective
5-HT2A antagonists)
RN 864297-53-0 CAPLUS
CN 1H-Indole-7-methanol, α -[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl-
(CA INDEX NAME)




RN 864297-54-1 CAPLUS

CN Methanone, [1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-1H-indol-7-yl- (CA INDEX NAME)



RN 864297-56-3 CAPLUS


CN 1H-Indole-7-methanol, α -[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro- (CA INDEX NAME)




RN 864297-57-4 CAPLUS

CN Ethanone, 2,2,2-trifluoro-1-[7-[(1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl)hydroxymethyl]-1H-indol-3-yl]- (CA INDEX NAME)


PAGE 1-A






RN 864297-59-6 CAPLUS

CN 1H-Indole-3-carbonitrile, 7-[[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]hydroxymethyl]- (CA INDEX NAME)



RN 864297-60-9 CAPLUS

CN 1H-Indole-3-carbonitrile, 7-[[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]carbonyl]- (CA INDEX NAME)




IT 864297-62-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and structure activity relations of
 (phenethylpiperidinyl)phenylethanols as potent and highly selective
 5-HT2A antagonists)

RN 864297-62-1 CAPLUS

CN 1H-Indole-7-methanol, 2,3-dihydro- α -4-piperidinyl- (CA INDEX NAME)



RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib hitstr 2

L8 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2007:1356517 CAPLUS


DN 148:92237

TI New Serotonin 5-HT6 Ligands from Common Feature Pharmacophore Hypotheses
 AU Kim, Hye-Jung; Doddareddy, Munikumar Reddy; Choo, Hyunah; Cho, Yong Seo;
 No, Kyoung Tai; Park, Woo-Kyu; Pae, Ae Nim

CS Life Science Division, Korea Institute of Science and Technology, Seoul,
 130-650, S. Korea

SO Journal of Chemical Information and Modeling (2008), 48(1), 197-206
 CODEN: JCISD8; ISSN: 1549-9596
 PB American Chemical Society
 DT Journal
 LA English
 IT 1000170-74-0
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (drug design, structure-activity profile and a sequential virtual screening procedure for new serotonin 5-HT6 ligands from common feature pharmacophore hypotheses)
 RN 1000170-74-0 CAPLUS
 CN Benzenesulfonamide, N-[7-[(2R,4S)-2-fluoro-4-piperidinyl]methyl]-1H-indol-5-yl]-2-methoxy-5-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib hitstr 1

L8 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2009:336963 CAPLUS
 DN 150:329617
 TI Substituted indolyl compounds as 5-HT6 ligands and their preparation, and use in the treatment of diseases
 IN Ramakrishna, Nirogi Venkata Satya; Shinde, Anil Karbhari; Kambhampati, Rama Sastri; Jasti, Venkateswarlu
 PA Suven Life Sciences Limited, India
 SO PCT Int. Appl., 64pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009034581	A1	20090319	WO 2008-IN280	20080502
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,				

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
 PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD,
 TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI IN 2007-CH2030 A 20070911

OS MARPAT 150:329617


IT 1131452-43-1P 1131452-44-2P 1131452-45-3P
 1131452-46-4P 1131452-47-5P 1131452-48-6P
 1131452-49-7P 1131452-50-0P 1131452-51-1P
 1131452-52-2P 1131452-53-3P 1131452-54-4P
 1131452-55-5P 1131452-56-6P 1131452-57-7P
 1131452-58-8P 1131452-59-9P 1131452-60-2P
 1131452-62-4P 1131452-63-5P 1131452-64-6P
 1131452-65-7P 1131452-66-8P 1131452-67-9P
 1131452-68-0P 1131452-69-1P 1131452-70-4P
 1131452-71-5P 1131452-72-6P 1131452-73-7P
 1131452-74-8P 1131452-75-9P 1131452-76-0P
 1131452-77-1P 1131452-78-2P 1131452-79-3P
 1131452-80-6P 1131452-81-7P 1131452-82-8P
 1131452-83-9P 1131452-84-0P 1131452-85-1P
 1131452-86-2P 1131452-87-3P 1131452-88-4P
 1131452-89-5P 1131452-90-8P 1131452-91-9P
 1131452-92-0P 1131452-93-1P 1131452-94-2P
 1131452-95-3P 1131452-96-4P 1131452-97-5P
 1131452-98-6P 1131452-99-7P 1131453-00-3P
 1131453-01-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of substituted indolyl compds. as 5-HT6 ligands useful in the treatment of diseases)


RN 1131452-43-1 CAPLUS

CN 1H-Indol-4-amine, 1-[(2-bromophenyl)sulfonyl]-N-(1-methyl-4-piperidinyl)-(CA INDEX NAME)



RN 1131452-44-2 CAPLUS


CN 1H-Indol-4-amine, 1-[(2-bromophenyl)sulfonyl]-N-4-piperidinyl-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 1131452-45-3 CAPLUS


CN 1H-Indol-4-amine, 1-[(2-bromophenyl)sulfonyl]-N-methyl-N-4-piperidinyl-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 1131452-46-4 CAPLUS

CN 1H-Indol-4-amine, 1-[(2-bromophenyl)sulfonyl]-N-ethyl-N- (1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-47-5 CAPLUS

CN 1H-Indol-4-amine, N-ethyl-1-[(4-methylphenyl)sulfonyl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-48-6 CAPLUS

CN 1H-Indol-4-amine, 1-[(2-chlorophenyl)sulfonyl]-N-ethyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-49-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[(3-chlorophenyl)sulfonyl]-1H-indol-4-yl]methylamino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1131452-50-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[methyl[1-[(4-(1-methylethyl)phenyl)sulfonyl]-1H-indol-4-yl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1131452-51-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1-[(4-fluorophenyl)sulfonyl]-1H-indol-4-yl)methylamino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1131452-52-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[methyl[1-[(3-(trifluoromethyl)phenyl)sulfonyl]-1H-indol-4-yl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1131452-53-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1-[(3-chlorophenyl)sulfonyl]-1H-indol-4-yl)amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1131452-54-4 CAPLUS


CN 1H-Indol-4-amine, 1-[(3-chlorophenyl)sulfonyl]-N-methyl-N-4-piperidinyl-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 1131452-55-5 CAPLUS


CN 1H-Indol-4-amine, 1-[(3-chlorophenyl)sulfonyl]-N-4-piperidinyl-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 1131452-56-6 CAPLUS

CN 1H-Indol-4-amine, 1-[(3-chlorophenyl)sulfonyl]-N-(1-methyl-4-piperidinyl)-
(CA INDEX NAME)



RN 1131452-57-7 CAPLUS


CN 1H-Indol-4-amine, 1-[(4-fluorophenyl)sulfonyl]-N-methyl-N-4-piperidinyl-,
hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 1131452-58-8 CAPLUS


CN 1H-Indol-4-amine, N-methyl-1-[4-(1-methylethyl)phenyl]sulfonyl]-N-4-piperidinyl-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 1131452-59-9 CAPLUS

CN 1H-Indol-4-amine, 1-[(4-fluorophenyl)sulfonyl]-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)




RN 1131452-60-2 CAPLUS

CN 1H-Indol-4-amine, 1-[(2,5-dimethoxyphenyl)sulfonyl]-N-methyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-62-4 CAPLUS


CN 1H-Indol-4-amine, N-methyl-1-[(4-methylphenyl)sulfonyl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-63-5 CAPLUS


CN 1H-Indol-4-amine, 1-[(2-chlorophenyl)sulfonyl]-N-methyl-N-(1-methyl-4-

piperidinyl)- (CA INDEX NAME)




RN 1131452-64-6 CAPLUS

CN 1H-Indol-4-amine, 1-[(4-fluorophenyl)sulfonyl]-N-methyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-65-7 CAPLUS

CN 1H-Indol-4-amine, 1-[(3-chlorophenyl)sulfonyl]-N-methyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-66-8 CAPLUS

CN 1H-Indol-4-amine, N-methyl-N-(1-methyl-4-piperidinyl)-1-[(3-(trifluoromethyl)phenyl)sulfonyl]- (CA INDEX NAME)




RN 1131452-67-9 CAPLUS

CN 1H-Indol-4-amine, N-methyl-1-[(4-(1-methylethyl)phenyl)sulfonyl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-68-0 CAPLUS

CN 1H-Indol-4-amine, 1-[(2-bromophenyl)sulfonyl]-N-methyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-69-1 CAPLUS

CN 1H-Indol-4-amine, 1-[(4-methoxyphenyl)sulfonyl]-N-methyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-70-4 CAPLUS

CN 1H-Indol-4-amine, N-(cyclopropylmethyl)-1-[(4-methylphenyl)sulfonyl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-71-5 CAPLUS


CN 1H-Indol-4-amine, 1-[(2-bromophenyl)sulfonyl]-N-(cyclopropylmethyl)-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-72-6 CAPLUS


CN 1H-Indol-4-amine, 1-[(2-chlorophenyl)sulfonyl]-N-(cyclopropylmethyl)-N-(1-

methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-73-7 CAPLUS

CN 1H-Indol-4-amine, N-(cyclopropylmethyl)-1-[(4-fluorophenyl)sulfonyl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-74-8 CAPLUS

CN 1H-Indol-4-amine, 1-[(3-chlorophenyl)sulfonyl]-N-(cyclopropylmethyl)-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-75-9 CAPLUS

CN 1H-Indol-4-amine, N-(cyclopropylmethyl)-N-(1-methyl-4-piperidinyl)-1-[(3-trifluoromethyl)phenylsulfonyl]- (CA INDEX NAME)




RN 1131452-76-0 CAPLUS

CN 1H-Indol-4-amine, N-(cyclopropylmethyl)-1-[(4-methoxyphenyl)sulfonyl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-77-1 CAPLUS

CN 1H-Indol-4-amine, N-(cyclopropylmethyl)-1-[(4-(1-methylethyl)phenyl)sulfonyl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-78-2 CAPLUS

CN 1H-Indol-4-amine, N-(1-methylethyl)-1-[(4-methylphenyl)sulfonyl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-79-3 CAPLUS

CN 1H-Indol-4-amine, 1-[(2-bromophenyl)sulfonyl]-N-(1-methylethyl)-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-80-6 CAPLUS

CN 1H-Indol-4-amine, 1-[(2-chlorophenyl)sulfonyl]-N-(1-methylethyl)-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-81-7 CAPLUS

CN 1H-Indol-4-amine, 1-[(4-fluorophenyl)sulfonyl]-N-(1-methylethyl)-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-82-8 CAPLUS

CN 1H-Indol-4-amine, 1-[(3-chlorophenyl)sulfonyl]-N-(1-methylethyl)-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-83-9 CAPLUS

CN 1H-Indol-4-amine, N-(1-methylethyl)-N-(1-methyl-4-piperidinyl)-1-[(3-(trifluoromethyl)phenyl)sulfonyl]- (CA INDEX NAME)




RN 1131452-84-0 CAPLUS

CN 1H-Indol-4-amine, 1-[(4-methoxyphenyl)sulfonyl]-N-(1-methylethyl)-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-85-1 CAPLUS

CN 1H-Indol-4-amine, N-(1-methylethyl)-1-[(4-(1-methylethyl)phenyl)sulfonyl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-86-2 CAPLUS

CN 1H-Indol-4-amine, N-(1-ethyl-4-piperidinyl)-1-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




RN 1131452-87-3 CAPLUS

CN 1H-Indol-4-amine, 1-[(2-bromophenyl)sulfonyl]-N-(1-ethyl-4-piperidinyl)-
(CA INDEX NAME)




RN 1131452-88-4 CAPLUS

CN 1H-Indol-4-amine, 1-[(2-chlorophenyl)sulfonyl]-N-(1-ethyl-4-piperidinyl)-
(CA INDEX NAME)




RN 1131452-89-5 CAPLUS

CN 1H-Indol-4-amine, N-(1-ethyl-4-piperidinyl)-1-[(4-fluorophenyl)sulfonyl]-
(CA INDEX NAME)




RN 1131452-90-8 CAPLUS

CN 1H-Indol-4-amine, 1-[(3-chlorophenyl)sulfonyl]-N-(1-ethyl-4-piperidinyl)-
(CA INDEX NAME)




RN 1131452-91-9 CAPLUS

CN 1H-Indol-4-amine, N-(1-ethyl-4-piperidinyl)-1-[(3-[trifluoromethyl]phenyl)sulfonyl]-
(CA INDEX NAME)




RN 1131452-92-0 CAPLUS

CN 1H-Indol-4-amine, N-(1-ethyl-4-piperidinyl)-1-[(4-methoxyphenyl)sulfonyl]-
(CA INDEX NAME)




RN 1131452-93-1 CAPLUS

CN 1H-Indol-4-amine, N-(1-ethyl-4-piperidinyl)-1-[[4-(1-methylethyl)phenyl]sulfonyl]- (CA INDEX NAME)




RN 1131452-94-2 CAPLUS

CN 1H-Indol-4-amine, 1-[(4-methylphenyl)sulfonyl]-N-(1-propyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-95-3 CAPLUS

CN 1H-Indol-4-amine, 1-[(2-bromophenyl)sulfonyl]-N-(1-propyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-96-4 CAPLUS

CN 1H-Indol-4-amine, 1-[(2-chlorophenyl)sulfonyl]-N-(1-propyl-4-piperidinyl)-
(CA INDEX NAME)




RN 1131452-97-5 CAPLUS

CN 1H-Indol-4-amine, 1-[(4-fluorophenyl)sulfonyl]-N-(1-propyl-4-piperidinyl)-
(CA INDEX NAME)




RN 1131452-98-6 CAPLUS


CN 1H-Indol-4-amine, 1-[(3-chlorophenyl)sulfonyl]-N-(1-propyl-4-piperidinyl)-
(CA INDEX NAME)




RN 1131452-99-7 CAPLUS
CN 1H-Indol-4-amine, N-(1-propyl-4-piperidinyl)-1-[[3-(trifluoromethyl)phenyl]sulfonyl]- (CA INDEX NAME)



RN 1131453-00-3 CAPLUS
CN 1H-Indol-4-amine, 1-[(4-methoxyphenyl)sulfonyl]-N-(1-propyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131453-01-4 CAPLUS
CN 1H-Indol-4-amine, 1-[[4-(1-methylethyl)phenyl]sulfonyl]-N-(1-propyl-4-piperidinyl)- (CA INDEX NAME)



IT 1131453-02-5P 1131453-03-6P 1131453-04-7P
1131453-05-8P 1131453-06-9P 1131453-07-0P
1131453-11-6P 1131453-12-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(intermediate; preparation of substituted indolyl compds. as 5-HT6 ligands
useful in the treatment of diseases)


RN 1131453-02-5 CAPLUS

CN 1H-Indol-4-amine, N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131453-03-6 CAPLUS

CN 1H-Indol-4-amine, N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)




RN 1131453-04-7 CAPLUS


CN 1H-Indol-4-amine, N-ethyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131453-05-8 CAPLUS
CN 1H-Indol-4-amine, N-methyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131453-06-9 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-(1H-indol-4-ylmethylamino)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1131453-07-0 CAPLUS
CN 1H-Indol-4-amine, N-methyl-N-4-piperidinyl- (CA INDEX NAME)




RN 1131453-11-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[(2-bromophenyl)sulfonyl]-1H-indol-4-yl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1131453-12-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[(2-bromophenyl)sulfonyl]-1H-indol-4-yl]methylamino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RE.CNT 2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> fil reg
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                                ENTRY          SESSION
FULL ESTIMATED COST          37.86          255.12
```

FILE 'REGISTRY' ENTERED AT 07:30:02 ON 28 MAY 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 26 MAY 2009 HIGHEST RN 1149431-57-1
 DICTIONARY FILE UPDATES: 26 MAY 2009 HIGHEST RN 1149431-57-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

```
=> s 1131453-03-6
L9          1 1131453-03-6
            (1131453-03-6/RN)
```

```
=> fil caplus
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                                ENTRY          SESSION
FULL ESTIMATED COST          0.48          255.60
```

FILE 'CAPLUS' ENTERED AT 07:30:12 ON 28 MAY 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
 held by the publishers listed in the PUBLISHER (PB) field (available
 for records published or updated in Chemical Abstracts after December
 26, 1996), unless otherwise indicated in the original publications.
 The CA Lexicon is the copyrighted intellectual property of the
 American Chemical Society and is provided to assist you in searching
 databases on STN. Any dissemination, distribution, copying, or storing
 of this information, without the prior written consent of CAS, is
 strictly prohibited.

FILE COVERS 1907 - 28 May 2009 VOL 150 ISS 22
 FILE LAST UPDATED: 27 May 2009 (20090527/ED)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:


<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate

```
=> s 19
L10          1 L9
=> d bib abs hitstr
```

```
L10  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2009 ACS on STN
AN  2009:336963  CAPLUS
DN  150:329617
TI  Substituted indolyl compounds as 5-HT6 ligands and their preparation, and
    use in the treatment of diseases
IN  Ramakrishna, Nirogi Venkata Satya; Shinde, Anil Karbhari; Kambhampati,
    Rama Sastri; Jasti, Venkateswarlu
PA  Suven Life Sciences Limited, India
SO  PCT Int. Appl., 64pp.
    CODEN: PIXXD2
DT  Patent
LA  English
FAN.CNT 1
```

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009034581	A1	20090319	WO 2008-IN280	20080502
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,				
	CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,				
	FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,				
	KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,				
	ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,				
	PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,				
	TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,				
	IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,				
	TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,				
	TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,				
	AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	IN 2007-CH2030	A	20070911		
OS	MARPAT 150:329617				
GI					



AB The invention relates to substituted indolyl compds. of formula I, their derivs., their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compns. containing them. Compds. of formula I wherein R is H, C1-3 alkyl, and C3-6 cycloalkyl; R1, R2 and R3 are independently H, halo, C1-3 (halo)alkyl, C3-6 cycloalkyl, and C1-3 (halo)alkoxy; R4 is H, C1-3 (halo)alkyl, aryl, aralkyl, C3-6 cycloalkyl and tert-butoxycarbonyl; m is 0 - 4; n and p are independently 0 - 5; are claimed. The invention also relates to a process for the preparation of above said compds., their derivs., their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compns. containing them. This invention also relates to the intermediates involved therein and process of their preparation. These compds. are useful in the treatment of various disorders that are related to 5-HT6 receptor functions. Example compound II was prepared by reductive amination of 1-methylpiperidin-4-one with 4-amino-1-(2-bromophenylsulfonyl)-1H-indole. All the invention compds. were evaluated for their 5-HT6 modulatory activity. From the assay, it was determined that compound II exhibited Ki value of 17.9 nM.


IT 1131453-03-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of substituted indolyl compds. as 5-HT₆ ligands useful in the treatment of diseases)

RN 1131453-03-6 CAPLUS


CN 1H-Indol-4-amine, N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)



RE.CNT 2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d 11
L1 HAS NO ANSWERS
L1 STR
```



```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
```

```
GRAPH ATTRIBUTES:
RSPEC 9 10 17
NUMBER OF NODES IS 25
```

```
STEREO ATTRIBUTES: NONE
```

```
=> s 11 ful
FULL SEARCH INITIATED 10:21:33 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 9156 TO ITERATE
```

```
100.0% PROCESSED 9156 ITERATIONS 30 ANSWERS
SEARCH TIME: 00.00.01
```

```
L3 30 SEA SSS FUL L1
```

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	187.80	188.52

```
FILE 'CAPLUS' ENTERED AT 10:21:37 ON 20 JUL 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Jul 2009 VOL 151 ISS 4
FILE LAST UPDATED: 19 Jul 2009 (20090719/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases will soon be updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 22.

=> s 13
L4 2 L3

=> d bib abs 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:198079 CAPLUS
DN 144:362583
TI 1-(1-Phenethylpiperidin-4-yl)-1-phenylethanols as potent and highly selective 5-HT2A antagonists
AU Heinrich, Timo; Boettcher, Henning; Pruecher, Helmut; Gottschlich, Rudolf; Ackermann, Karl-August; van Amsterdam, Christoph
CS Preclinical Pharmaceutical Research, Merck KGaA, Darmstadt, 64293, Germany
SO ChemMedChem (2006), 1(2), 245-255
CODEN: CHEMGX; ISSN: 1860-7179
PB Wiley-VCH Verlag GmbH & Co. KGaA
DT Journal
LA English
AB The discovery of a novel class of highly potent and selective 5-HT2A antagonists is reported herein. Selectivity for the serotonin 5-HT2A receptor was optimized, decreasing the affinity of these antagonists toward the adrenergic α 1 and dopaminergic D2 receptors, and especially to the 5-HT2C receptor. A series of corresponding 7-substituted indoles is described for the first time as serotonergic ligands. The enantiomer R-(+)-1-(4-fluorophenyl)-1-{1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl}ethanol was identified to have superior affinity for the serotonergic 5-HT2A receptor [IC50 = 0.37 nM] and selectivity toward the dopaminergic D2- [IC50 = 2300 nM], adrenergic α 1- [IC50 = 1000 nM] and 5-HT2C receptors [IC50 = 490 nM].


RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:979638 CAPLUS
DN 143:286283
TI Preparation of 7-(4-piperidinylmethyl)indoles as potent 5-HT2a antagonists
IN Heinrich, Timo; Boettcher, Henning; Leibrock, Joachim
PA Merck Patent G.m.b.H., Germany
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2

DT Patent
LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005082886	A1	20050909	WO 2005-EP1446	20050214
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 102004010132	A1	20050915	DE 2004-102004010132	20040227
	AU 2005217043	A1	20050909	AU 2005-217043	20050214
	CA 2557489	A1	20050909	CA 2005-2557489	20050214
	EP 1718634	A1	20061108	EP 2005-715322	20050214
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	JP 2007523930	T	20070823	JP 2007-500098	20050214
	US 20070197596	A1	20070823	US 2006-590912	20060828
PRAI	DE 2004-102004010132	A	20040227		
	WO 2005-EP1446	W	20050214		
OS	MARPAT 143:286283				
GI					




AB Title compds. I [A = (R2)n; B = (X)m; X = H, halo, CN, etc.; Y = CHR2CHR2, CR2=CR2; Q = O, OH, NH, etc.; R1 = (un)substituted alkylcycloalkyl, alkylaryl, alkylheteroaryl; R2 = H, alkyl, alkylaryl; n, m = 1-3] and

their pharmaceutically acceptable salts and formulations were prepared. For example, 4-fluorophenethyl mesylatealkylation of piperidine II afforded piperidinylmethylindole III. Compds. I are claimed to be 5-HT2a antagonists (no data provided).

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d 11
L1 HAS NO ANSWERS
L1 STR
```



```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
```

```
GRAPH ATTRIBUTES:
RSPEC 9 10 17
NUMBER OF NODES IS 25
```

```
STEREO ATTRIBUTES: NONE
```

```
=> s 11 ful
FULL SEARCH INITIATED 10:21:33 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 9156 TO ITERATE
```

```
100.0% PROCESSED 9156 ITERATIONS 30 ANSWERS
SEARCH TIME: 00.00.01
```

```
L3 30 SEA SSS FUL L1
```

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	187.80	188.52

```
FILE 'CAPLUS' ENTERED AT 10:21:37 ON 20 JUL 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Jul 2009 VOL 151 ISS 4
FILE LAST UPDATED: 19 Jul 2009 (20090719/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases will soon be updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 22.

=> s 13
L4 2 L3

=> d bib abs 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:198079 CAPLUS
DN 144:362583
TI 1-(1-Phenethylpiperidin-4-yl)-1-phenylethanols as potent and highly selective 5-HT2A antagonists
AU Heinrich, Timo; Boettcher, Henning; Pruecher, Helmut; Gottschlich, Rudolf; Ackermann, Karl-August; van Amsterdam, Christoph
CS Preclinical Pharmaceutical Research, Merck KGaA, Darmstadt, 64293, Germany
SO ChemMedChem (2006), 1(2), 245-255
CODEN: CHEMGX; ISSN: 1860-7179
PB Wiley-VCH Verlag GmbH & Co. KGaA
DT Journal
LA English
AB The discovery of a novel class of highly potent and selective 5-HT2A antagonists is reported herein. Selectivity for the serotonin 5-HT2A receptor was optimized, decreasing the affinity of these antagonists toward the adrenergic α 1 and dopaminergic D2 receptors, and especially to the 5-HT2C receptor. A series of corresponding 7-substituted indoles is described for the first time as serotonergic ligands. The enantiomer R-(+)-1-(4-fluorophenyl)-1-{1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl}ethanol was identified to have superior affinity for the serotonergic 5-HT2A receptor [IC50 = 0.37 nM] and selectivity toward the dopaminergic D2- [IC50 = 2300 nM], adrenergic α 1- [IC50 = 1000 nM] and 5-HT2C receptors [IC50 = 490 nM].


RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:979638 CAPLUS
DN 143:286283
TI Preparation of 7-(4-piperidinylmethyl)indoles as potent 5-HT2a antagonists
IN Heinrich, Timo; Boettcher, Henning; Leibrock, Joachim
PA Merck Patent G.m.b.H., Germany
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2

DT Patent
LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005082886	A1	20050909	WO 2005-EP1446	20050214
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 102004010132	A1	20050915	DE 2004-102004010132	20040227
	AU 2005217043	A1	20050909	AU 2005-217043	20050214
	CA 2557489	A1	20050909	CA 2005-2557489	20050214
	EP 1718634	A1	20061108	EP 2005-715322	20050214
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	JP 2007523930	T	20070823	JP 2007-500098	20050214
	US 20070197596	A1	20070823	US 2006-590912	20060828
PRAI	DE 2004-102004010132	A	20040227		
	WO 2005-EP1446	W	20050214		
OS	MARPAT 143:286283				
GI					



AB Title compds. I [A = (R2)n; B = (X)m; X = H, halo, CN, etc.; Y = CHR2CHR2, CR2=CR2; Q = O, OH, NH, etc.; R1 = (un)substituted alkylcycloalkyl, alkylaryl, alkylheteroaryl; R2 = H, alkyl, alkylaryl; n, m = 1-3] and

their pharmaceutically acceptable salts and formulations were prepared. For example, 4-fluorophenethyl mesylatealkylation of piperidine II afforded piperidinylmethylindole III. Compds. I are claimed to be 5-HT2a antagonists (no data provided).

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT